1,2-bis-(4-phenyl-1-piperazinyl)-ethanes

ABSTRACT

This invention relates to therapeutically useful 1,2-bis-(4phenyl-1-piperazinyl)-ethane derivatives having the formula:   IN WHICH R1 and R2 represent independently from each other a radical selected from the halogens, the trifluoromethyl radical and the lower alkyl radicals.

United States Patent 11 1 Bouchara 51 Aug. 26, 1975 1,2-BlS-(4-PHENYL- l-PIPERAZINYL ETHANES [76] Inventor: Emile Bouchara, 75 bis, Ave. Foch,

75 Paris, France [22] Filed: May 29, 1973 [21] App]. No: 364,328

[30] Foreign Application Priority Data June 2, I972 France 72.19903 52 0.5. CI. 260/268 PH; 260/268 Bl; 424/250 5 1 1m. cl. c071) 295/06 58 Field of Search 260/268 Bl. 268 PH [56] References Cited UNITED STATES PATENTS l/l97l Klccmann et all 260/268 Bl 4/[972 McCarty 260/268 Bl Primary Examiner-Donald G. Daus Assistant Examiner-Jose Tovar Attorney, Agent, or Firm-Young & Thompson [57] ABSTRACT This invention relates to therapeutically useful l,2-bis- (4-phenyl-l-piperazinylyethane derivatives having the formula:

7 Claims, No Drawings l,2-BlS-(4-PHENYL-l-PlPERAZINYL)-ETHANES This invention relates to pipcrazinyl )-ethane derivatives.

This invention provides new l,2bis-(4-phenyl-lpiperazinyl)-ethane derivatives having the formula:

1,2-bis-(4-phenyll in which R, has the above-defined meaning, and of a halogen derivative having the formula in which R has the above-defined meaning and X is halogen, typically chlorine,

or, in the case of the production of compounds in which R and R are the same, of a halogen derivative having the formula:

in which X is halogen, typically bromine, by refluxing within a suitably boiling organic solvent, particularly isopropanol, in the presence of an acid acceptor, particularly potassium carbonate. The reaction is advantageously carried out by using stoichiometric amounts of the reagents.

The compounds of the formula (II!) may be prepared from the corresponding hydroxyl compounds by reaction with a thionyl halide within a solvent such as methylene chloride.

The com pounds of this invention possess useful pharmacologic properties. They possess particularly hypolipemia inducing properties and also analgesic and antiinflammatory properties. Moreover, the compounds have a low toxicity and may be used for therapeutic purposes. Thus. this invention includes also within its scope a therapeutic composition having particularly a hypolipemia-inducing activity, comprising a compound of the formula (I) or an acid addition salt thereof with therapeutically acceptable acids, together with a therapeutically acceptable carrier. The compounds may be used for oral. transcutaneous or rectal administration,

2 or may also be used for topical applications on the skin and the mucous membranes.

The compounds may be formulated as solutions or suspensions for injection in ampoules or multiple-dosage vials, or as tablets, coated tablets, capsules, syrups, suppositories and ointments.

The daily dosage regimen for adults is comprised within a range from 5 mg to 500 mg, depending on the route of administration and on the desired effect. The pharmaceutically usable forms such as injectable solutions or suspensions, tablets or coated tablets, syrups, suppositories and ointments are prepared according to the methods usually employed in the pharmaceutical art.

The following examples are given to illustrate the invention without, however, limiting same.

EXAMPLE 1 l ,2-bis-(4-m-Trifluoromethylphenyl-1-piperazinyl)- ethane Analysis (3 P1,, F, N, 486.49

0% 11% F% N% Calculated: 59.25 5.30 23.43 11.52 Found; 59.10 5.34 23.51 11.43

EXAMPLE 2 Dimaleate of the compound of Example 1 The dimaleate is obtained by heating in ethanol a stoichiometric solution of 1,2-bis-(4-m-trifluoromethylphenyl-l-piperazinyl)-ethane and maleic acid. White crystals. M.p. 228230C.

Analysis C H F N 0,, 718.64

Calculated: 53.48 5.05 15.86 7.80

Found: 53.64 5.13 15.92 8.04

EXAMPLE 3 Difumarate of the Compound of Example 1 The difumarate is obtained by heating in ethanol a stoichiometric solution of l,2-bis-(4-m-trifluoromethylphenyl-l-piperazinyl)-ethane and fumaric acid. White crystals. M.p. 248250C.

Analysis? :12 an e 7l8b4 C?! H F'Z N i Calculated: 53 48 ()5 i586 Found; 53.59 5.1 l i592 7.94

EXAMPLE 4 1 ,2-bis-( 4-o-Fluorophenyll -piperazinyl )-ethane l'he same procedure is used as in Example 1. White 5 'stals. M.p. 136C (ethanol).

llysit c 11., F, N. 386.47

culated: 68.37 7.30 9.83

Ind: 68.04 7.26 9.512

EXAMPLE 1 ,2-bis-( 4-m-Fluorophenyl- 1 -piperazinyl )-ethane "he same procedure is used as in Example 1. White stals. M.p. 140C (ethanol).

11 ,316: c 11,, F, N, 386.47

(3% 11% we llllalbdl 68.37 7.30 9.33 Dd: 68.46 7.30 9.56

EXAMPLE 6 1 ,2-bis-( 4-p-Fluorophenyll -piperazinyl )-ethane he same procedure is used as in Example 1. White stals. M.p. 171C (isopropanol).

1Iysis: 12, 11,. F, N4 386.47

:ulated: 68.37 7.30 9.83

EXAMPLE 7 I ,2-bis-( 4-m-Chloropheny1- l -piperazinyl )-ethane he same procedure is used as in Example 1. Beige stals. M.p. 138C.

lysis: 0,, 11,. (:1, N. 419.38

016 m 14% 161mm; 63.00 6.73 13.36 60: 62.64 6.93 12.96

EXAMPLE 8 l ,2'bis-( 4-o-tolyll -piperazinyl )-ethane he same procedure is used as in Example 1. White itals. M.p. 98C.

EXAMPLE 9 1,2-bis-(4-m-tolyl- 1 -piperazinyl )-ethane he same procedure is used as in Example 1. White 11.1118. M.p. 143T.

Analysis; C l-l N 378.54

11% N% Calculated: 76. 14 9.05 1 4.30 Found: 76.28 9.10 14.76

EXAMPLE 1O 1 ,2-bis-( 4-p-Tolyl- I -piperazinyl )-ethane The same procedure is used as in Example 1. White crystals. M.p. 202C.

Analysis: 0,. 11,. N. 3713.54

C% 11% 19% Calculated: 76.14 9.05 14.80 Found: 76.22 9.10 15.00

EXAMPLE l 1 l-(4-o-Fluorophenyl-1-piperazinyl)-2-(4-pfluorophenyl- 1 piperazinyl )-ethane Analysis: C: H F, N 386.47

1101 F N; Calculated: 68.37 7.30 9.83 14.50 Found: 68.35 7.24 9.55 14.54

EXAMPLE l2 l-(4-o-F1uorophenyl- I -piperazinyl )-2-( 4-m-chlorophenyl- 1 -piperaziny1)ethane The same procedure is used as in Example 1 1. Beige crystals. M.p. 112C (ethyl acetate).

Analysis: H Cl F N, 402.93

FOUMI 65.47 7.00 8.91 4.72 13.75

EXAMPLE 13 1-( 4-m-Trifluoromethylphenyl- 1 -piperaz1ny1 )-2-( 4-mchlorophenyll -piperazinyl )-ethane The same procedure is used as in Example 11. Light yellow crystals. M.p. 87C (isopropunol).

H01 ("I'll F! N' Calculated; 60.99 6.23 7.83 12.58 12.37 Found: 60.77 6.32 7.75 12.59 12.25

1. Acute toxicity determination EXAMPLE 14 The acute toxicity tests were conducted with lots of l-(4-m-Trifluoromethylphenyl-l-piperazinyl)-2-(4-ol female Swiss" strain mice weighing l921 g. The

tolyl-l-piperazinyl)-ethane LD by the oral route was determined according to The same procedure is used as in Example ll. Pale KARBEB and BEHRENS method after 48 hours of observation.

ll tal.M. .=90C bt l-h 1:1. ye 0w crys S p u ano exdne All the compounds of this invention were found to have low toxicity. The results obtained are summarized Analysis: C B F N4 43152 in the Table given hereinafter. Calculated 54 7 IS l S 3 5s ypollpemla'mfjucmg acnvity Found; 66:89 1 5 Said hypolipemia-inducing activity was evidenced in adult normal rats after ingestion of each of the compounds during four consecutive days. The dosages used are relatively low.

EXAMPLE The serum triglyceride and cholesterol levels were 1 (4 t ifl th l h l i i 2 (4 determined according to KESSLER and LEDERER's l j i l h (Automation in Analytical Chemistry, ed., L. T.

SKEGGS, New York 1965, 341 and J. LEVINE and B. The same procedure is used as in Example ll. Light ZAKS (Clin Chim Acta 1964 lo 38]) Semi beige crystals. M.p. 100C (butanol). automatic technique.

Under the same conditions, the clofibrate (LD 1600 mg/kg by the oral route) at a dosage of 100 mg/kg Aria] sis: C H F N =432.52

y a q (3% H% F% N% decreases the triglycerides by a factor of 33% and the Calculated: 66.64 7.23 l3.18 12.95 cholesterol by a factor f Found: 6630 7.15 l3.70 i281 The results obtained are summarized in the Table given hereinafter.

3. Analgesic activity EXAMPLE 16 The analgesic activity was determined by the inhibition test on the peritoneal pain induced by injection of acetic acid in mice.

This test is based on the observation made by The Same procedure is used as in Example Beige KOSTER and coworkers (Fed. Proc. 1959, l8, 412 y l -P- lac l' according to which intraperitoneal injection of 0.2 ml/2O g of a 6 AQ acetic acid solution induces in mice writhing and stretching motions. The compounds havl -(4-m-Trifluoromethylphenyl-1-pipera2inyl )-2-(4-p- 30 tolyll -piperaZinyl)-ethane Analym: 21 3 H% We N% ing an analgesic action attenuate or suppress this syn Calculated. 66.64 7.23 l3. is 12.95 drome. Found: 6695 12-66 Lots of l0 mice were administered orally the various test compounds, 30 minutes prior to the challenging agent. The stretching motions were counted during 15 EXAMPLE 17 minutes and the analgesic effect was expressed as percent decrease of the number of stretching motions with respect to the control animals.

Under the same conditions, acetylsalicylic acid (LD The same procedure is used as in Example I 1. Light about 1500 mg/kg by the oral route) at a dosage of l-( 4-m-Trifluoromethylphenyll -piperazinyl )-2-( 4-pfluorophenyll -piperazinyl )-ethane yellow crystals. M.p. 238C (ethanol). 100 mg/kg by the oral route gave a percent protection The results obtained are summarized in the Table Analysis: C3| HM F4 N, 06.7 668.63 Hr? F% N% given he inafter Calculated: 55.6 8 5.4; 11.37 8.38 50 Ami-iflflammatory activity Found: 55.47 5.31 1 [.64 8.64 The anti-inflammatory activity was determined in rats by means of the carrhageenin induced oedema of the paw.

Rats weighing about l20 g are administered 0.] ml of EXAMPLE [8 an 0.5% carrhageenin suspension (plantar sub-aponeu- The Sam? Procedure is used as in Example 1 White rotic injection) 1 hour after oral treatment with the var- CryStalS. Mp 2 lious compounds of this invention.

The volume of the rear paws is measured prior to injection of the inflammatory agent, and 2, 3 and 4 hours Anajyss 66863 H7 F% N% after said injection. The anti-inflammatory activity is Calculated: 55.68 5.43 1 1 37 8.38 expressed as percent protection with respect to the Found: 55 44 5.39 l 1.47 8.39 1 animals- Under the same conditions. indometacine (LD 50 mg/kg, by the oral route) at a dosage of 5 mg/kg afiords The results of toxicological and pharmacological 30% protection which l f the highly useful pmpgmes of The results obtained are summarized in the Table compounds of this invention are set forth below. given hereinafter I. A compound of the formula:

LD HYPOLlPEMlA-INDUCING ACTIVITY ANALGESIC ACTIVH'Y ANTI-INFLAMMATORY ACITVI'IY ompound of mglkg p.o Dmage Dosage Protection Dosage Protection lxample mg/kg p.o. Triglyc. Cholcstrug/kg p.o rug/kg p.0.

l 3200 S 40 52 40 50 40 38 3 29) 7.5 37 62 I9 60 68 60 25 2 3200 7.5 29 50 I: 60 73 I20 51 l3 3200 I 40 48 9b 40 59 4O 30 i: 7 32(1) I0 19 k 49.5 80 53 8O 32 l8 l2) 7 l7.5 -34.5 55 68 H0 14% 17 I200 7 19 I: 50.5 14 65.5 55 22 12 I460 IO 31 k 29 73 64 96 I46 26 l1 24(1) 10 33 47.5 I 58 240 50 k 4 880 4O 22.5 44 64 88 17 5 3200 I0 22 36 37 X: 40 66 7a 320 I4 6 25(1) l0 -35.5 46.5 1 4| 44 5| b 8 3200 I0 5.5 l5 4O k 320 25 I: 9 2910 10 3.5 36 9 64 51 Ill) 37 I0 3200 10 28 l: 32.5 I0 70 320 25 I: I4 2910 I0 25 76 -35 73 7| 290 35% I5 1200 I0 25 44 k 64 k 120 16 3%!) l0 l2 43.5 k 40 58 i: 320 72 I;

I claim: or its addition salts with therapeutically acceptable acids.

5. l-( 4-o-Fluorophenyl-l-piperazinyl)-2-(4-pfluorophenyl-l-piperazinyl)-ethane or its addition salts with therapeutically acceptable acids.

6. l 4-m-Trifluoromethylphen yll piperazinyl )-2- (4-m-chlorophenyl-l-piperazinyl)-ethane or its addition salts with therapeutically acceptable acids.

7. l-( 4-Trifluoromethylphenyll -piperazinyl )-2-( 4- p-fluorophenyl-l-piperazinyI)-ethane or its addition salts with therapeutically acceptable acids.

* Q i i 

1. A COMPOUND OF THE FORMULA:
 2. 1,2-Bis-(4-m-Trifluoromethylphenyl-1-piperazinyl)-ethane or its addition salts with therapeutically acceptable acids.
 3. 1,2-Bis-(4-p-fluorophenyl-1-piperazinyl)-ethane or its addition salts with therapeutically acceptable acids.
 4. 1,2-Bis-(4-m-chlorophenyl-1-piperazinyl)-ethane or its addition salts with therapeutically acceptable acids.
 5. 1-(4-o-Fluorophenyl-1-piperazinyl)-2-(4-p-fluorophenyl-1-piperazinyl)-ethane or its addition salts with therapeutically acceptable acids.
 6. 1-(4-m-Trifluoromethylphenyl-1-piperazinyl)-2-(4-m-chlorophenyl-1 -piperazinyl)-ethane or its addition salts with therapeutically acceptable acids.
 7. 1-(4-Trifluoromethylphenyl-1-piperazinyl)-2-(4-p-fluorophenyl-1-piperazinyl)-ethane or its addition salts with therapeutically acceptable acids. 